Clinical trials: Chronic Pulmonary Obstruction
Pulmonary Disease, Chronic Obstructive
Preference Tiotropium Respimat Study in COPD
In COPD the patient's ability to use inhalers correctly and their preference for the inhaler are both important factors in selecting an appropriate treatment for COPD.
- Trial name
- NCT01810692
- Testing
- Group1:Spiriva® Respimat®, Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®
- Where
- 15 sites in Spain
- Volunteers
- 150 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care
This is a prospective, observational, non-drug interventional, non-randomized study to compare the rate of moderate-severe COPD exacerbations in patients of all Chronic Obstructive Pulmonary Disease (COPD) severities with and…
- Trial name
- ACCESS (NCT01516528)
- Testing
- Spirometry
- Where
- 233 sites in Belgium, France and 4 more
- Volunteers
- 3,500 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR)
Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD
This study is a randomized, double-blind, double-dummy, parallel group study to compare once daily nebulized Revefenacin with Spiriva once daily delivered via the HandiHaler® on lung function in subjects with COPD and a Low Peak…
- Trial name
- NCT03095456
- Testing
- Revefenacin, Spiriva Handihaler®
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
The main purpose of this study is to assess if different dose levels of Brenipatide are safe and work the way they are intended to work in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), when…
- Trial name
- RENEW-COPD (NCT07759245)
- Testing
- Brenipatide, Standard of Care
- Where
- 127 sites in United States, Argentina and 16 more
- Volunteers
- 606 people
- Sponsor
- Eli Lilly and Company
Chronic Obstructive Pulmonary Disease
Exacerbations and Real-World Outcomes Among Patients With Chronic Obstructive Pulmonary Disease Following Severe Exacerbation
This real-world retrospective study will use de-identified administrative claims data and will examine patients with a diagnosis of COPD who have experienced a qualifying severe disease exacerbation and received subsequent…
- Trial name
- NCT07414134
- Testing
- BGF- BUDESONIDE/GLYCOPYRRONIUM/FORMOTEROL
- Where
- United States
- Volunteers
- 3,598 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients
The purpose of this study is to assess the safety and tolerability of PUR0200. In addition, the study will look at the blood levels of different doses of PUR0200 and their affect on lung function in COPD patients.
- Trial name
- NCT01921712
- Testing
- PUR0200, Active comparator
- Where
- 2 sites in United Kingdom
- Volunteers
- 38 people
- Sponsor
- Pulmatrix Inc.
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD
To evaluate the 1-year efficacy and safety of the fixed combination beclometasone/formoterol pMDI in a twice daily regimen in patients with stable severe COPD.
- Trial name
- NCT00476099
- Testing
- Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI, Budesonide 200 µg plus formoterol 6 µg DPI, Formoterol 12 µg DPI
- Where
- France
- Volunteers
- 828 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Chronic Obstructive Pulmonary Disease
Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients
In MediciNova's clinical development plan for MN-221, it was recognized that treatment of COPD exacerbations may necessitate more than one single i.v.
- Trial name
- NCT01551316
- Testing
- MN-221
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Chronic Obstructive Pulmonary Disease
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects
Groups 1, 3, 4, 5 and 6 of this research team adopted a single-center, open-label design. Group 2 used a three-sequence, three-period crossover design, where participants in this dose group were randomly assigned to the three…
- Trial name
- NCT07267130
- Testing
- TQC3302 inhalation spray, TQC3302 inhalation spray+Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation, Tiotropium bromide and olodaterol hydrochloride inhalation spray +Budesonide Powder for Inhalation+ TQC3302 inhalation spray
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical (Guangzhou) Co., Ltd.
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Study to Evaluate the Clinical Value and Safety of Xiyanping Injection in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease(COPD) Based on Real-world Clinical Data
The primary objective is to evaluate the effect of Xiyanping injection on the treatment course of intravenous antibiotics for acute exacerbation of chronic obstructive pulmonary disease based on real-world clinical data, and to…
- Trial name
- XYP-202401 (NCT06754865)
- Testing
- Xiyanping injection+ antibiotic, Antibiotic
- Volunteers
- 1,140 people
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Respiratory Disorders
Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
The aim of this study is to generate epidemiological data to further explore determinants of Chronic Obstructive Pulmonary Disease (COPD) and the contribution of bacterial and viral pathogens to Acute Exacerbation of COPD…
- Trial name
- NCT01360398
- Testing
- Blood sample, Sputum sample, Nasopharyngeal swab
- Where
- United Kingdom
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
This is a Phase III multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the efficacy and safety of two doses of GSK573719/GW642444 Inhalation Powder and GW642444 Inhalation Powder via a Novel Dry…
- Trial name
- NCT01316900
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444
- Where
- 97 sites in United States, France and 8 more
- Volunteers
- 846 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease (COPD), Asthma
Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD
The purpose of this study is to assess the safety and tolerability of single doses of LAS190792 administered by inhalation to patients with mild persistent asthma and moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT02059434
- Testing
- LAS190792 Dose 1, LAS190792 Dose 2, LAS190792 Dose 3
- Where
- 2 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Chronicling the COPD Patient Journey and Change in COPD Symptoms, Quality of Life and Exacerbations Following Initiation of Budenoside/Glycopyrronium/Formoterol [BGF]
The CHRONICLES study will investigate the change in clinical and patient reported outcomes after six-months of treatment with Budenoside/Glycopyrronium/Formoterol [BGF] in a real-world setting.
- Trial name
- CHRONICLES (NCT06511193)
- Testing
- Budenoside/Glycopyrronium/Formoterol
- Where
- Canada
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B
This is a phase III multicenter, randomized, double-blind, placebo-controlled, combination and component, two-period, incomplete block design cross-over study using GSK573719/GW642444.
- Trial name
- COPD (NCT01323660)
- Testing
- GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125
- Where
- 53 sites in United States, Canada and 5 more
- Volunteers
- 307 people
- Sponsor
- GlaxoSmithKline
COPD
A Multi-center Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of R7103 Following Repeated Inhalation in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease
This study will assess the safety, tolerability, pharmacodynamics, and pharmacokinetics of RO5024118 following repeated inhalation in patients with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD).
- Trial name
- NCT01009424
- Testing
- R7103
- Sponsor
- Hoffmann-La Roche
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Tolerability of Symbicort as an add-on Treatment to Spiriva Compare With Spiriva Alone in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD)
This is a multicentre study with a randomised, parallel group, open-label, 3-month phase IV design to assess the efficacy and tolerability of Symbicort as an add-on treatment to Spiriva compare with Spiriva alone in patients with…
- Trial name
- SECURE 1 (NCT01397890)
- Testing
- Budesonide/formoterol (Symbicort® Turbuhaler®), Tiotropium (SpirivaTM)
- Where
- 31 sites in China, Hong Kong and 3 more
- Volunteers
- 793 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase II study is to evaluate the pharmacokinetics, safety, and tolerability of aclidinium/formoterol fixed dose combination (FDC 400/12 μg via the Almirall Inhaler and formoterol 12 μg via the Foradil®…
- Trial name
- NCT01551888
- Testing
- Aclidinium/formoterol 400/12μg, Formoterol
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Lung Disease Causing Persistent Narrowing of the Airways
AZD2115 Single Ascending Dose Study
AZD2115 Single Ascending Dose Study
- Trial name
- NCT01283984
- Testing
- AZD2115
- Where
- United Kingdom
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Bronchitis, Chronic Obstructive Pulmonary Disease
A Clinical Evaluation of the RheOx Bronchial Rheoplasty System
This is a prospective, multicenter, single arm and open-label clinical trial to evaluate the performance, effectiveness and safety of RheOx™ system in the treatment of the symptoms of chronic bronchitis in adult moderate to…
- Trial name
- NCT05641207
- Testing
- RheOx™ with the RheOx™ Catheter treated in the trial
- Where
- 7 sites in China
- Volunteers
- 40 people
- Sponsor
- Energenx Medical LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.